New Zealand - English - Medsafe (Medicines Safety Authority)

mundipharma new zealand ltd - oxycodone hydrochloride 30mg equivalent to 27 mg oxycodone base - modified release tablet - 30 mg - active: oxycodone hydrochloride 30mg equivalent to 27 mg oxycodone base excipient: lactose monohydrate magnesium stearate methacrylic acid copolymer opadry brown ys-1-16518-a povidone purified talc stearyl alcohol triacetin - the management of moderate to severe chronic pain unresponsive to non-narcotic analgesia

New Zealand - English - Medsafe (Medicines Safety Authority)

mundipharma new zealand ltd - oxycodone hydrochloride 40mg;  ;   - modified release tablet - 40 mg - active: oxycodone hydrochloride 40mg     excipient: ammonio methacrylate copolymer lactose monohydrate magnesium stearate opadry yellow ys-1-12525-a povidone purified talc stearyl alcohol triacetin - the management of moderate to severe chronic pain unresponsive to non-narcotic analgesia

New Zealand - English - Medsafe (Medicines Safety Authority)

mundipharma new zealand ltd - oxycodone hydrochloride 5mg equivalent to 4.5 mg of oxycodone base;   - modified release tablet - 5 mg - active: oxycodone hydrochloride 5mg equivalent to 4.5 mg of oxycodone base   excipient: ammonio methacrylate copolymer brilliant blue fcf hypromellose lactose monohydrate macrogol 400 magnesium stearate opadry blue 06b20843 povidone purified talc stearyl alcohol titanium dioxide triacetin - the management of moderate to severe chronic pain unresponsive to non-narcotic analgesia.

New Zealand - English - Medsafe (Medicines Safety Authority)

mundipharma new zealand ltd - oxycodone hydrochloride 60mg - modified release tablet - 60 mg - active: oxycodone hydrochloride 60mg excipient: ammonio methacrylate copolymer lactose monohydrate magnesium stearate opadry red 15b25501 povidone purified talc purified water stearyl alcohol triacetin - the management of moderate to severe chronic pain unresponsive to non-narcotic analgesia.

New Zealand - English - Medsafe (Medicines Safety Authority)

mundipharma new zealand ltd - oxycodone hydrochloride 80mg;  ;   - modified release tablet - 80 mg - active: oxycodone hydrochloride 80mg     excipient: ammonio methacrylate copolymer lactose monohydrate magnesium stearate opadry green y-5-11167-a povidone purified talc stearyl alcohol triacetin - the management of moderate to severe chronic pain unresponsive to non-narcotic analgesia

New Zealand - English - Medsafe (Medicines Safety Authority)

mundipharma new zealand ltd - naloxone hydrochloride dihydrate 5.45mg equivalent to naloxone hydrochloride anhydrous 5 mg; oxycodone hydrochloride 10mg;   - modified release tablet - 10/5mg - active: naloxone hydrochloride dihydrate 5.45mg equivalent to naloxone hydrochloride anhydrous 5 mg oxycodone hydrochloride 10mg   excipient: ethylcellulose lactose monohydrate magnesium stearate opadry white 85f18422 povidone purified talc   stearyl alcohol - the management of moderate to severe chronic pain unresponsive to non-narcotic analgesia. the naloxone component in a fixed combination with oxycodone is indicated for the therapy and/or prophylaxis of opioid-induced constipation.

New Zealand - English - Medsafe (Medicines Safety Authority)

mundipharma new zealand ltd - naloxone hydrochloride dihydrate 10.9mg equivalent to naloxone hydrochloride anhydrous 10 mg; oxycodone hydrochloride 20mg;   - modified release tablet - 20/10mg - active: naloxone hydrochloride dihydrate 10.9mg equivalent to naloxone hydrochloride anhydrous 10 mg oxycodone hydrochloride 20mg   excipient: ethylcellulose lactose monohydrate magnesium stearate opadry pink 85f24151 povidone purified talc   stearyl alcohol - the management of moderate to severe chronic pain unresponsive to non-narcotic analgesia. the naloxone component in a fixed combination with oxycodone is indicated for the therapy and/or prophylaxis of opioid-induced constipation.

New Zealand - English - Medsafe (Medicines Safety Authority)

mundipharma new zealand ltd - naloxone hydrochloride dihydrate 21.8mg equivalent to naloxone hydrochloride anhydrous 20 mg; oxycodone hydrochloride 40mg;   - modified release tablet - 40/20mg - active: naloxone hydrochloride dihydrate 21.8mg equivalent to naloxone hydrochloride anhydrous 20 mg oxycodone hydrochloride 40mg   excipient: ethylcellulose lactose monohydrate magnesium stearate opadry yellow 85f32109 povidone purified talc   stearyl alcohol - the management of moderate to severe chronic pain unresponsive to non-narcotic analgesia. the naloxone component in a fixed combination with oxycodone is indicated for the therapy and/or prophylaxis of opioid-induced constipation.

New Zealand - English - Medsafe (Medicines Safety Authority)

mundipharma new zealand ltd - naloxone hydrochloride dihydrate 2.73mg equivalent to naloxone hydrochloride anhydrous 2.5 mg; oxycodone hydrochloride 5mg;   - modified release tablet - 5/2.5mg - active: naloxone hydrochloride dihydrate 2.73mg equivalent to naloxone hydrochloride anhydrous 2.5 mg oxycodone hydrochloride 5mg   excipient: ethylcellulose hyprolose lactose monohydrate magnesium stearate opadry blue 85f30569 purified talc   stearyl alcohol - the management of moderate to severe chronic pain unresponsive to non-narcotic analgesia. the naloxone component in a fixed combination with oxycodone is indicated for the therapy and/or prophylaxis of opioid-induced constipation.

New Zealand - English - Medsafe (Medicines Safety Authority)

mundipharma new zealand ltd - dorzolamide hydrochloride 2.226%{relative} equivalent to dorzolamide base 2% - eye drops, solution - 2 % - active: dorzolamide hydrochloride 2.226%{relative} equivalent to dorzolamide base 2% excipient: benzalkonium chloride hyetellose mannitol sodium citrate dihydrate sodium hydroxide water for injection - trusopt ophthalmic solution is indicated in the treatment of elevated intraocular pressure in patients with: · ocular hypertension · open-angle glaucoma · pseudoexfoliative glaucoma and other secondary open-angle glaucomas · in the short-term treatment of paediatric glaucomas as adjunctive therapy to beta-blockers and for monotherapy when other treatments have proved ineffective or are unsuitable.